The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Second-line regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) after progression on first-line atezolizumab plus bevacizumab (Atezo-Bev): Phase 2 REGONEXT trial.
 
Changhoon Yoo
Honoraria - AstraZeneca; Bayer; Boryung Pharmaceuticals; Bristol-Myers Squibb; Celgene; Eisai; Ipsen; MSD Oncology; Novartis; SERVIER
Research Funding - AstraZeneca; Bayer; SERVIER
 
Jaekyung Cheon
Consulting or Advisory Role - Eisai; Roche
Speakers' Bureau - Eisai
Research Funding - Bayer
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Min-Hee Ryu
Honoraria - AstraZeneca; Bristol-Myers Squibb; Daehwa Pharmaceutical; Daiichi Sankyo; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; Daehwa Pharmaceutical; Lilly; Ono Pharmaceutical
 
Hyung-Don Kim
Honoraria - AstraZeneca; Boostimmune; Boryung Pharmaceuticals; Bristol-Myers Squibb; Ono Pharmaceutical
 
Kyu-Pyo Kim
No Relationships to Disclose
 
Beodeul Kang
No Relationships to Disclose
 
Hong Jae Chon
Consulting or Advisory Role - AstraZeneca; Bayer; BMS; Celgene Cancer Care Links/BMS; Eisai; Green Cross; Menarini; MSD Oncology; Ono Pharmaceutical; Roche; Sanofi; SERVIER; Sillajen
Speakers' Bureau - Bayer; BMS; Celgene/Bristol-Myers Squibb; Dong-A ST; Eisai; Menarini; Roche; Sanofi; SERVIER
Research Funding - Boryung (Inst); Dong-A ST (Inst); Roche (Inst)
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Hengrui Therapeutics; Lilly; Merck; Pfizer
Speakers' Bureau - Genentech
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)